Tocagen — Forte Biosciences — Investor Presentation (May 2022)
12 slides from Tocagen's investor presentation, May 16, 2022
Slide 1: Forte Biosciences Corporate Presentation May 2022
Forte biosciences Developing treatments for Autoimmune diseases Corporate PRESENTATION May 2022 Exhibit 99.2
Slide 2: Forward-looking statements
Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These inc
Slide 3: Summary of Forte Biosciences
Summary OF Forte Biosciences: POTENTIAL first-in-class biotherapeutic for the treatment of Autoimmune diseases Examples of large market with unmet need Alopecia Areata (AA) It is estimated that alopecia areata affects 700,000 people in the US with moderate to severe at 300,000 people (NIH) The globa
Slide 4: Overview of FB-102 Therapeutic Molecule
FORTE BIOSCIENCES: Overview of FB-102 Therapeutic Molecule Antagonism of pathway for autoimmune disease Proprietary molecule developed entirely and wholly-owned by Forte Multi-billion dollar revenue potential Preclinical PoC validates target Significant unmet need in autoimmune diseases including po
Slide 5: Experienced management and advisory teams
EXPERIENCED management and advisory Teams Paul Wagner, PhD, CFA – CEO Forte's team has extensive experience in manufacturing, quality, and regulatory and clinical development in autoimmune disorders Scientific Advisory Board (SAB) Steve Doberstein, PhD – Former Head of Research and Development at Ne
Slide 6: Board with extensive public company experience
BOARD with extensive public company experience Board with strong track record at public companies Steve Doberstein, PhD – Former Head of Research and Development at Nektar Therapeutics Prof. Lawrence Eichenfield, MD – Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Dieg
Slide 7: Alopecia Areata overview
Alopecia Areata overview Alopecia Areata (AA) is characterized by nonscarring hair loss generally on the scalp but can also other areas of the body AA is an autoimmune disease in which immune cells attack and damage hair follicles There remains a significant unmet need for safe and effective therapi
Slide 8: Graft-vs-Host-Disease/Transplant rejection overview
Graft-vs-Host-Disease/Transplant rejection overview Graft-versus-host disease (GvHD) is a common potentially life-threatening complication associated with allogeneic hematopoietic stem cell transplantation (HSCT) in which the transplanted cells initiate an immune response against the transplant reci
Slide 9: Vitiligo overview
Vitiligo overview Vitiligo is characterized by the loss of melanocytes which are cells that produce skin pigmentation Vitiligo results in discolored patches appearing in the skin, hair and mucous membrane Vitiligo is an autoimmune disease in which the immune system attack melanocytes It is estimated
Slide 10: FB-102 has potential in several other autoimmune diseases
FB-102 has potential in several other autoimmune diseases Eosinophilic esophagitis Atopic Dermatitis Celiac Disease Type 1 Diabetes Ulcerative colitis Non-Alcoholic Steatohepatitis (NASH)
Slide 11: Pipeline
Pipeline Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 FB-102 Alopecia Areata GvHD Vitiligo Celiac Disease Forte expects FB-102 to be in the clinic in the second half of 2023 Forte cash on hand expected to be sufficient for at least the next 24 months
Slide 12: Summary of Forte Biosciences
Summary OF Forte Biosciences: POTENTIAL first-in-class biotherapeutic for the treatment of Autoimmune diseases Examples of large market with unmet need Alopecia Areata (AA) It is estimated that alopecia areata affects 700,000 people in the US with moderate to severe at 300,000 people (NIH) The globa